CPA4 (Gene)

Organism:

Homo sapiens

Synonyms:CPA3, CPA4, ENTREZ:51200, HGNC:15740, MIM:607635, NM_001163446, NM_016352, NP_001156918, NP_057436, carboxypeptidase A4

Omim:OMIM:607635

Id:bf7f8dcf-29e5-5d90-aeac-1ddaf7072e19

Hgnc:HGNC:15740

Entrez:51200

Ensembl:ENSG00000128510

Description:carboxypeptidase A4

This gene is a member of the carboxypeptidase A/B subfamily, and it is located in a cluster with three other family members on chromosome 7. Carboxypeptidases are zinc-containing exopeptidases that catalyze the release of carboxy-terminal amino acids, and are synthesized as zymogens that are activated by proteolytic cleavage. This gene could be involved in the histone hyperacetylation pathway. It is imprinted and may be a strong candidate gene for prostate cancer aggressiveness. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CPA4's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CPA4.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CPA4.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CPA4.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CPA4.

Results found

Linked to

	Label	Description
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE208634 1 V 2 DOXYCYCLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE208634 1 V 2 DOXYCYCLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.